If either of the durvalumab plus BCG (cohort 2a) or the durvalumab plus EBRT (cohort 2b) establishes a RP2D in Phase 1 of the study, enrollment to Phase 2 of the study will proceed. Upon successful screening and registration, Phase 2 subjects will be randomized to one of the treatment arms. Randomization will occur amongst the arms that are open to accrual at the time of subject registration. With the exception of patients assigned to BCG re-treatment, treatment of Phase 2 subjects will be administered at the RP2D's established for each regimen within Phase 1 of the study. Given the established safety profile of BCG therapy, patients assigned to BCG re-treatment within Phase 2 of the study will be treated with full dose BCG (dose level 0).